Hostname: page-component-7b7567c8c-wxvwp Total loading time: 0 Render date: 2026-11-17T21:20:49.172Z Has data issue: false hasContentIssue false

Effect of Methylprednisolone on CSF IgG Parameters, Myelin Basic Protein and Anti-Myelin Basic Protein in Multiple Sclerosis Exacerbations

Published online by Cambridge University Press:  18 September 2015

Kenneth G. Warren*
Affiliation:
Department of Medicine (Neurology), Department of Laboratory Medicine (Endocrinology) and Rehabilitation Medicine of the University of Alberta, Edmonton
Ingrid Catz
Affiliation:
Department of Medicine (Neurology), Department of Laboratory Medicine (Endocrinology) and Rehabilitation Medicine of the University of Alberta, Edmonton
Verona M. Jeffrey
Affiliation:
Department of Medicine (Neurology), Department of Laboratory Medicine (Endocrinology) and Rehabilitation Medicine of the University of Alberta, Edmonton
Dorothy J. Carroll
Affiliation:
Department of Medicine (Neurology), Department of Laboratory Medicine (Endocrinology) and Rehabilitation Medicine of the University of Alberta, Edmonton
*
9 - 101 Clinical Sciences Building, 112 Street & 83 Avenue, Edmonton, Alberta, Canada T6G 2G3
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

Clinical exacerbations of multiple sclerosis (MS) are characterized by elevated levels of cerebrospinal fluid (CSF) myelin basic protein (MBP). The purposes of this study were to determine whether anti-MBP antibodies are present in increased titer in CSF of MS patients with exacerbations, and whether they can be suppressed by the administration of immunosuppressive dosages of methylprednisolone (MP). A solid phase radio-immunoassay (RIA) was used to detect free and total anti-MBP antibodies before and after acid hydrolysis of CSF. In MS exacerbations, the majority of elevated anti-MBP is in the free form. With the exception of subacute sclerosing panencephalitis (SSPE) and some cases of post infectious encephalomyelitis, anti-MBP antibodies are not present in either MS patients in remission or in non-MS controls. Anti-MBP levels remained elevated over a 10 day period when patients are managed by bed rest only or when treated with intravenous (IV) ACTH. IV administration of MP in “high” (160 mg/day) or “mega” (2 g/day) dosages produces a highly significant reduction of both MBP (p<0.01) and anti-MBP (p<0.001) levels. Total intrathecal IgG synthesis is also significantly suppressed by IV-MP but not by ACTH.

Information

Type
Original Articles
Copyright
Copyright © Canadian Neurological Sciences Federation 1986